Immune targeting of PD-1hi expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques

Virology

Volumn 447, Issue 1-2, 2013, Pages 274-284

  Vargas Inchaustegui, Diego A ^a   Xiao, Peng ^a,d   Hogg, Alison E ^a,e   Demberg, Thorsten ^a   McKinnon, Katherine ^a   Venzon, David ^a   Brocca Cofano, Egidio ^a,f   DiPasquale, Janet ^a   Lee, Eun M ^b   Hudacik, Lauren ^b   Pal, Ranajit ^b   Sui, Yongjun ^a   Berzofsky, Jay A ^a   Liu, Linda ^c   Langermann, Solomon ^c   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^c Amplimmune Inc   (United States)

^d EMORY UNIVERSITY   (United States)

^e Aeras ^*  (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

ART; Immunomodulation; PD 1; Treg; Viremia

Indexed keywords

ALPHA4BETA7 INTEGRIN; ANTIRETROVIRUS AGENT; B7 ANTIGEN DENDRITIC CELL IMMUNOGLOBULIN FUSION PROTEIN; IMMUNOMODULATING AGENT; INTEGRIN; KI 67 ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; FEMALE; IMMUNOMODULATION; IMMUNOPHENOTYPING; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TOXICITY TESTING; UPREGULATION; VIREMIA; VIRUS LOAD;

ART; IMMUNOMODULATION; PD-1; TREG; VIREMIA;

ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MACACA MULATTA; PROGRAMMED CELL DEATH 1 RECEPTOR; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T-LYMPHOCYTES; VIRAL LOAD;

EID: 84885195905     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.09.015     Document Type: Article

References (68)

1. Ansari A.A., Reimann K.A., Mayne A.E., Takahashi Y., Stephenson S.T., Wang R., Wang X., Li J., Price A.A., Little D.M., Zaidi M., Lyles R., Villinger F. Blocking of alpha4beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J. Immunol. 2011, 186:1044-1059.
2. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
3. Benlhassan-Chahour K., Penit C., Dioszeghy V., Vasseur F., Janvier G., Riviere Y., Dereuddre-Bosquet N., Dormont D., Le Grand R., Vaslin B. Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy. J. Virol. 2003, 77:12479-12493.
4. Calza L. Renal toxicity associated with antiretroviral therapy. HIV Clin. Trials 2012, 13:189-211.
5. + T cells in peripheral blood after initiation of highly active antiretroviral therapy. J. Virol. 2001, 75:6508-6516.
6. Chattopadhyay P.K., Roederer M. Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV disease. Cytometry A 2010, 77:614-622.
7. Chevalier M.F., Weiss L. The split personality of regulatory T cells in HIV infection. Blood 2013, 121:29-37.
8. Conrad J.A., Ramalingam R.K., Duncan C.B., Smith R.M., Wei J., Barnett L., Simons B.C., Lorey S.L., Kalams S.A. Antiretroviral therapy reduces the magnitude and T cell receptor repertoire diversity of HIV-specific T cell responses without changing T cell clonotype dominance. J. Virol. 2012, 86:4213-4221.
9. Curiel T.J., Wei S., Dong H., Alvarez X., Cheng P., Mottram P., Krzysiek R., Knutson K.L., Daniel B., Zimmermann M.C., David O., Burow M., Gordon A., Dhurandhar N., Myers L., Berggren R., Hemminki A., Alvarez R.D., Emilie D., Curiel D.T., Chen L., Zou W. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9:562-567.
10. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., DePierres C., Mncube Z., Duraiswamy J., Zhu B., Eichbaum Q., Altfeld M., Wherry E.J., Coovadia H.M., Goulder P.J., Klenerman P., Ahmed R., Freeman G.J., Walker B.D. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
11. Demberg T., Brocca-Cofano E., Xiao P., Venzon D., Vargas-Inchaustegui D., Lee E.M., Kalisz I., Kalyanaraman V.S., Dipasquale J., McKinnon K., Robert-Guroff M. Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J. Virol. 2012, 86:12591-12604.
12. Fauci A.S., Desrosiers R.C. Pathogenesis of HIV and SIV. Retroviruses 1997, Cold Spring Harbor, (NY). J.M. Coffin, S.H. Hughes, H.E. Varmus (Eds.).
13. Finnefrock A.C., Tang A., Li F., Freed D.C., Feng M., Cox K.S., Sykes K.J., Guare J.P., Miller M.D., Olsen D.B., Hazuda D.J., Shiver J.W., Casimiro D.R., Fu T.M. PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J. Immunol. 2009, 182:980-987.
14. + Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest. 2009, 119:551-564.
15. Francisco L.M., Sage P.T., Sharpe A.H. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 2010, 236:219-242.
16. Goujard C., Girault I., Rouzioux C., Lécuroux C., Deveau C., Chaix M.L., Jacomet C., Talamali A., Delfraissy J.F., Venet A., Meyer L., Sinet M. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir. Ther. 2012, 17:1001-1009. ANRS CO6 PRIMO Study Group.
17. Grabmeier-Pfistershammer K., Steinberger P., Rieger A., Leitner J., Kohrgruber N. Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J. Acquir. Immune Defic. Syndr. 2011, 56:118-124.
18. Ha S.J., Mueller S.N., Wherry E.J., Barber D.L., Aubert R.D., Sharpe A.H., Freeman G.J., Ahmed R. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J. Exp. Med. 2008, 205:543-555.
19. Holmes D., Jiang Q., Zhang L., Su L. Foxp3 and Treg cells in HIV-1 infection and immuno-pathogenesis. Immunol. Res. 2008, 41:248-266.
20. (+) T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J. Immunol. 2012, 188:3247-3256.
21. Hong J.J., Amancha P.K., Rogers K., Ansari A.A., Villinger F. Re-evaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection. PLoS One 2013, 8:e60186.
22. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992, 11:3887-3895.
23. Jin H.T., Anderson A.C., Tan W.G., West E.E., Ha S.J., Araki K., Freeman G.J., Kuchroo V.K., Ahmed R. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. U.S.A 2010, 107:14733-14738.
24. (+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol. 2009, 2:439-449.
25. + but show differential infection based on alpha4beta7 receptor expression during acute SIV infection. J. Med. Primatol. 2009, 38(Suppl 1):24-31.
26. Kalams S.A., Goulder P.J., Shea A.K., Jones N.G., Trocha A.K., Ogg G.S., Walker B.D. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 1999, 73:6721-6728.
27. + T cells during acute HCV infection, irrespective of clinical outcome. J. Virol. 2008, 82:3154-3160.
28. Kaufmann D.E., Walker B.D. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J. Immunol. 2009, 182:5891-5897.
29. Keir M.E., Liang S.C., Guleria I., Latchman Y.E., Qipo A., Albacker L.A., Koulmanda M., Freeman G.J., Sayegh M.H., Sharpe A.H. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 2006, 203:883-895.
30. Kim P.S., Ahmed R. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 2010, 22:223-230.
31. Klatt N.R., Vinton C.L., Lynch R.M., Canary L.A., Ho J., Darrah P.A., Estes J.D., Seder R.A., Moir S.L., Brenchley J.M. SIV infection of rhesus macaques results in dysfunctional T- and B-cell responses to neo and recall Leishmania major vaccination. Blood 2011, 118:5803-5812.
32. Lee E.M., Chung H.K., Livesay J., Suschak J., Finke L., Hudacik L., Galmin L., Bowen B., Markham P., Cristillo A., Pal R. Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. J. Virol. Methods 2010, 163:287-294.
33. (+) PD-1 expression is related to HBeAg seroconversion in hepatitis B patients on pegylated interferon. Chin. Med. J. (Engl.) 2013, 126:267-273.
34. Macatangay B.J., Rinaldo C.R. PD-1 blockade: a promising immunotherapy for HIV?. Cellscience 2009, 5:61-65.
35. Margolis D.M. Eradication therapies for HIV Infection: time to begin again. AIDS Res. Hum. Retroviruses 2011, 27:347-353.
36. Messal N., Serriari N.E., Pastor S., Nunes J.A., Olive D. PD-L2 is expressed on activated human T cells and regulates their function. Mol. Immunol. 2011, 48:2214-2219.
37. Mkrtichyan M., Najjar Y.G., Raulfs E.C., Abdalla M.Y., Samara R., Rotem-Yehudar R., Cook L., Khleif S.N. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur. J. Immunol. 2011, 41:2977-2986.
38. Mkrtichyan M., Najjar Y.G., Raulfs E.C., Liu L., Langerman S., Guittard G., Ozbun L., Khleif S.N. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J. Immunol. 2012, 189:2338-2347.
39. Moore R.D., Keruly J.C., Bartlett J.G. Improvement in the health of HIV-infected persons in care: reducing disparities. Clin. Infect. Dis. 2012, 55:1242-1251.
40. (+) T cell responses. Vaccine 2011, 29:3169-3176.
41. Moreno-Fernandez M.E., Presicce P., Chougnet C.A. Homeostasis and function of regulatory T cells in HIV/SIV infection. J. Virol. 2012, 86:10262-10269.
42. Nakamoto N., Kaplan D.E., Coleclough J., Li Y., Valiga M.E., Kaminski M., Shaked A., Olthoff K., Gostick E., Price D.A., Freeman G.J., Wherry E.J., Chang K.M. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 2008, 134:1927-1937.
43. Norde W.J., Hobo W., van der Voort R., Dolstra H. Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood 2012, 120:728-736.
44. + effector memory insufficiency and overt disease in chronic SIV infection. J. Exp. Med. 2007, 204:2171-2185.
45. Pace M.J., Agosto L., Graf E.H., O'Doherty U. HIV reservoirs and latency models. Virology 2011, 411:344-354.
46. Pegu P., Vaccari M., Gordon S., Keele B.F., Doster M., Guan Y., Ferrari G., Pal R., Ferrari M.G., Whitney S., Hudacik L., Billings E., Rao M., Montefiori D., Tomaras G., Alam S.M., Fenizia C., Lifson J.D., Stablein D., Tartaglia J., Michael N., Kim J., Venzon D., Franchini G. Antibodies with high avidity to the gp120 envelope protein in protection from SIVmac251 acquisition in an immunization regimen that mimics the RV-144 Thai trial. J. Virol. 2012, 87:1708-1719.
47. Pereira L.E., Villinger F., Onlamoon N., Bryan P., Cardona A., Pattanapanysat K., Mori K., Hagen S., Picker L., Ansari A.A. Simian immunodeficiency virus (SIV) infection influences the level and function of regulatory T cells in SIV-infected rhesus macaques but not SIV-infected sooty mangabeys. J. Virol. 2007, 81:4445-4456.
48. Perreau M., Savoye A.L., De Crignis E., Corpataux J.M., Cubas R., Haddad E.K., De Leval L., Graziosi C., Pantaleo G. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J. Exp. Med. 2013, 210:143-156.
49. + T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood 2007, 110:928-936.
50. Porichis F., Kaufmann D.E. Role of PD-1 in HIV pathogenesis and as target for therapy. Curr. HIV/AIDS Rep. 2012, 9:81-90.
51. Porichis F., Kwon D.S., Zupkosky J., Tighe D.P., McMullen A., Brockman M.A., Pavlik D.F., Rodriguez-Garcia M., Pereyra F., Freeman G.J., Kavanagh D.G., Kaufmann D.E. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 2011, 118:965-974.
52. Riley J.L. PD-1 signaling in primary T cells. Immunol. Rev. 2009, 229:114-125.
53. Rodriguez-Garcia M., Porichis F., de Jong O.G., Levi K., Diefenbach T.J., Lifson J.D., Freeman G.J., Walker B.D., Kaufmann D.E., Kavanagh D.G. Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J. Leukoc. Biol. 2011, 89:507-515.
54. Rosenblatt J., Glotzbecker B., Mills H., Vasir B., Tzachanis D., Levine J.D., Joyce R.M., Wellenstein K., Keefe W., Schickler M., Rotem-Yehudar R., Kufe D., Avigan D. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 2011, 34:409-418.
55. Sakthivel P., Gereke M., Bruder D. Therapeutic intervention in cancer and chronic viral infections: antibody mediated manipulation of PD-1/PD-L1 interaction. Rev. Recent Clin. Trials 2012, 7:10-23.
56. Salisch N.C., Kaufmann D.E., Awad A.S., Reeves R.K., Tighe D.P., Li Y., Piatak M., Lifson J.D., Evans D.T., Pereyra F., Freeman G.J., Johnson R.P. Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. J. Immunol. 2010, 184:476-487.
57. Sellier P., Mannioui A., Bourry O., Dereuddre-Bosquet N., Delache B., Brochard P., Calvo J., Prevot S., Roques P. Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination. PLoS One 2010, 5:e10570.
58. + Treg cells in chronic HCV infected-patients. Virol. J. 2011, 8:279.
59. Shin H., Wherry E.J. CD8 T cell dysfunction during chronic viral infection. Curr. Opin. Immunol. 2007, 19:408-415.
60. Singh A.K., Stock P., Akbari O. Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy 2011, 66:155-162.
61. Suchard M.S., Mayne E., Green V.A., Shalekoff S., Donninger S.L., Stevens W.S., Gray C.M., Tiemessen C.T. FOXP3 expression is upregulated in CD4T cells in progressive HIV-1 infection and is a marker of disease severity. PLoS One 2010, 5:e11762.
62. Tzeng H.T., Tsai H.F., Liao H.J., Lin Y.J., Chen L., Chen P.J., Hsu P.N. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One 2012, 7:e39179.
63. Velu V., Titanji K., Zhu B., Husain S., Pladevega A., Lai L., Vanderford T.H., Chennareddi L., Silvestri G., Freeman G.J., Ahmed R., Amara R.R. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009, 458:206-210.
64. Vezys V., Penaloza-MacMaster P., Barber D.L., Ha S.J., Konieczny B., Freeman G.J., Mittler R.S., Ahmed R. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J. Immunol. 2011, 187:1634-1642.
65. Wherry E.J. T cell exhaustion. Nat. Immunol. 2011, 12:492-499.
66. Xiao P., Patterson L.J., Kuate S., Brocca-Cofano E., Thomas M.A., Venzon D., Zhao J., DiPasquale J., Fenizia C., Lee E.M., Kalisz I., Kalyanaraman V.S., Pal R., Montefiori D., Keele B.F., Robert-Guroff M. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J. Virol. 2012, 86:4644-4657.
67. Yao Z.Q., King E., Prayther D., Yin D., Moorman J. T cell dysfunction by hepatitis C virus core protein involves PD-1/PDL-1 signaling. Viral. Immunol. 2007, 20:276-287.
68. + T cells. Curr. Opin. Immunol. 1998, 10:444-449.